Hedge Funds Boost Valeant Positions
Armstrong Henry H Associates Inc. boosted its position in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) by 27.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 252,907 shares of the specialty pharmaceutical company’s stock after buying an additional 54,633 shares during the period. Valeant Pharmaceuticals Intl makes up about 5.0% of Armstrong Henry H Associates Inc.’s investment portfolio, making the stock its 8th largest position. Armstrong Henry H Associates Inc. owned 0.07% of Valeant Pharmaceuticals Intl worth $25,708,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to their stakes in the company.
Janus Capital Management raised its position in Valeant Pharmaceuticals Intl by 36.1% in the third quarter. Janus Capital Management now owns 3,258,686 shares of the specialty pharmaceutical company’s stock worth $581,295,000 after buying an additional 863,566 shares during the last quarter.
Gillespie Robinson & Grimm raised its position in Valeant Pharmaceuticals Intl by 12.3% in the fourth quarter. Gillespie Robinson & Grimm now owns 123,815 shares of the specialty pharmaceutical company’s stock worth $12,586,000 after buying an additional 13,525 shares during the last quarter.
Deltec Asset Management LLC acquired a new position in Valeant Pharmaceuticals Intl during the fourth quarter worth approximately $610,000. Nebula Capital Management LP raised its position in Valeant Pharmaceuticals Intl by 264.0% in the fourth quarter.
Nebula Capital Management LP now owns 64,800 shares of the specialty pharmaceutical company’s stock worth $6,587,000 after buying an additional 47,000 shares during the last quarter.
Finally, Candriam Luxembourg S.C.A. raised its position in Valeant Pharmaceuticals Intl by 48.1% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 27,011 shares of the specialty pharmaceutical company’s stock worth $2,744,000 after buying an additional 8,768 shares during the last quarter.
Armstrong Henry H Associates Inc. boosted its position in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) by 27.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 252,907 shares of the specialty pharmaceutical company’s stock after buying an additional 54,633 shares during the period. Valeant Pharmaceuticals Intl makes up about 5.0% of Armstrong Henry H Associates Inc.’s investment portfolio, making the stock its 8th largest position. Armstrong Henry H Associates Inc. owned 0.07% of Valeant Pharmaceuticals Intl worth $25,708,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to their stakes in the company.
Janus Capital Management raised its position in Valeant Pharmaceuticals Intl by 36.1% in the third quarter. Janus Capital Management now owns 3,258,686 shares of the specialty pharmaceutical company’s stock worth $581,295,000 after buying an additional 863,566 shares during the last quarter.
Gillespie Robinson & Grimm raised its position in Valeant Pharmaceuticals Intl by 12.3% in the fourth quarter. Gillespie Robinson & Grimm now owns 123,815 shares of the specialty pharmaceutical company’s stock worth $12,586,000 after buying an additional 13,525 shares during the last quarter.
Deltec Asset Management LLC acquired a new position in Valeant Pharmaceuticals Intl during the fourth quarter worth approximately $610,000. Nebula Capital Management LP raised its position in Valeant Pharmaceuticals Intl by 264.0% in the fourth quarter.
Nebula Capital Management LP now owns 64,800 shares of the specialty pharmaceutical company’s stock worth $6,587,000 after buying an additional 47,000 shares during the last quarter.
Finally, Candriam Luxembourg S.C.A. raised its position in Valeant Pharmaceuticals Intl by 48.1% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 27,011 shares of the specialty pharmaceutical company’s stock worth $2,744,000 after buying an additional 8,768 shares during the last quarter.
